Drug Type Small molecule drug |
Synonyms 오에수아이마린점안액 |
Mechanism 11β-HSD1 inhibitors(Corticosteroid 11-beta-dehydrogenase isozyme 1 inhibitors), GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists), Plasminogen activators inhibitors + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (17 Oct 2024), |
Regulation- |
Molecular FormulaC10H11N3O3S |
InChIKeyJLKIGFTWXXRPMT-UHFFFAOYSA-N |
CAS Registry723-46-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Blepharitis | KR | 17 Oct 2024 | |
Conjunctivitis | KR | 17 Oct 2024 | |
Hordeolum | KR | 17 Oct 2024 |